Trials / Terminated
TerminatedNCT06317285
A Study to Evaluate the Efficacy and Safety of GSK3915393 in Participants With Idiopathic Pulmonary Fibrosis (IPF)
A Phase 2, Randomized, Double-Blind, Placebo Controlled, Parallel Group Study (TRANSFORM) to Evaluate the Efficacy and Safety of GSK3915393 in Participants With Idiopathic Pulmonary Fibrosis (IPF)
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 158 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Idiopathic Pulmonary Fibrosis is a chronic lung disease which causes scarring of the lungs and difficulty in breathing. GSK3915393 is a new medicine, which is being tested in participants with IPF for the first time. The study will assess the safety and effectiveness of GSK3915393 in IPF participants.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | GSK3915393 | GSK3915393 will be administered. |
| DRUG | Placebo | Placebo will be administered. |
Timeline
- Start date
- 2024-04-04
- Primary completion
- 2025-10-01
- Completion
- 2025-10-01
- First posted
- 2024-03-19
- Last updated
- 2026-03-13
Locations
56 sites across 10 countries: United States, Argentina, Canada, France, Germany, Italy, Netherlands, Poland, Spain, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06317285. Inclusion in this directory is not an endorsement.